Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$22.54
+5.0%
$18.68
$2.03
$14.36
$211.83M1.1150,104 shs89,846 shs
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$1.16
$0.98
$4.95
$69.47M2.34396,682 shs296,500 shs
Acelyrin, Inc. stock logo
SLRN
Acelyrin
$2.27
$2.27
$1.85
$7.25
$229.17M1.071.28 million shsN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$5.00
$5.00
$2.29
$5.30
$266.15M1.04643,143 shsN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-3.55%+5.87%+8.65%+99.35%-53.07%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
0.00%0.00%0.00%+3.18%-67.85%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
0.00%0.00%0.00%+0.40%+1.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00
N/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
2.40
Hold$9.60322.91% Upside
2seventy bio, Inc. stock logo
TSVT
2seventy bio
2.00
Hold$5.00N/A

Current Analyst Ratings Breakdown

Latest OSMT, TSVT, SLRN, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/10/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
4/24/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$177.88M0.00N/A1.00$1.50 per share0.00
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/A$6.74 per shareN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$48.37M5.50N/AN/A$5.04 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%8/12/2025 (Estimated)
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)

Latest OSMT, TSVT, SLRN, and NLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$0.71N/AN/AN/AN/AN/A
8/6/2025Q2 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.05N/AN/AN/A$15.45 millionN/A
5/14/2025Q1 2025
Acelyrin, Inc. stock logo
SLRN
Acelyrin
-$0.95-$0.55+$0.40-$0.55N/AN/A
5/7/2025Q1 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/A
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/A
0.43
0.42
Acelyrin, Inc. stock logo
SLRN
Acelyrin
N/A
7.15
7.15
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/A
4.95
4.95

Institutional Ownership

CompanyInstitutional Ownership
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
46.18%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
87.31%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
93.90%

Insider Ownership

CompanyInsider Ownership
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
5.22%
Acelyrin, Inc. stock logo
SLRN
Acelyrin
13.60%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
30262.59 million59.32 millionNot Optionable
Acelyrin, Inc. stock logo
SLRN
Acelyrin
135100.95 million86.68 millionOptionable
2seventy bio, Inc. stock logo
TSVT
2seventy bio
44053.23 million47.87 millionOptionable

Recent News About These Companies

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year
2seventy Bio price target lowered to $5 from $6 at Morgan Stanley
2seventy bio accepts Bristol Myers’ takeover bid
2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

New MarketBeat Followers Over Time

Media Sentiment Over Time

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$22.54 +1.07 (+4.98%)
As of 07/16/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Osmotica Pharmaceuticals stock logo

Osmotica Pharmaceuticals NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Acelyrin stock logo

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

2seventy bio stock logo

2seventy bio NASDAQ:TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.